Thon Vojtěch
Ustav klinicke imunologie a alergologie, Lekarska fakulta, Masarykovy University a FN u sv. Anny v Brne.
Epidemiol Mikrobiol Imunol. 2013 Jul;62(2):64-73.
Patients with agammaglobulinaemia and hypogammaglobulinaemia require immunoglobulin G (IgG) replacement therapy to prevent serious infections. Since the 1950s, therapy with human immune globulin products has been the standard of treatment. Currently, the most common routes of administration of IgG replacement therapy are intravenous (IVIG) or subcutaneous (SCIG). The home therapy may improve the quality of life in patients who require lifelong IgG replacement. The -anti-IgA antibody test identifies the patients with the risk of anaphylactoid reactions in IVIG replacement. The SCIG delivery may be used in patients with anti-IgA antibodies and previous systemic reactions to IVIG.
无丙种球蛋白血症和低丙种球蛋白血症患者需要免疫球蛋白G（IgG）替代疗法来预防严重感染。自20世纪50年代以来，用人免疫球蛋白产品进行治疗一直是治疗的标准方法。目前，IgG替代疗法最常见的给药途径是静脉注射（IVIG）或皮下注射（SCIG）。家庭治疗可能会改善需要终身IgG替代治疗的患者的生活质量。抗IgA抗体检测可识别IVIG替代治疗中有过敏样反应风险的患者。对于有抗IgA抗体且既往对IVIG有全身反应的患者，可使用SCIG给药。
